CTLA4 and colitis: Although radiologic manifestations of irAEs—such as those clinically evident (colitis, hypophysitis, and arthritis) and those clinically silent (benign lymphadenopathy and inflammatory changes in soft tissue), all assessed by the standard methods of tumor imaging—are associated with significant clinical benefit of anti-CTLA-4 therapy [114], the potential link between irAEs and clinical benefit awaits further confirmation and clarification.